Ariel Focus Fund outperformed benchmarks with a 7.30% gain in Q1 2026 despite market volatility. Read the full analysis for ...
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma TA1149 30 April 2026 30 April 2026 Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or ...
Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results